Login to Your Account



DUOver: Verastem proves duvelisib in CLL phase III

By Randy Osborne
Staff Writer

Wednesday, September 6, 2017

Eagerly awaited data from Verastem Inc.'s phase III DUO study should "more than satisfy the skeptics," CEO Robert Forrester told BioWorld as the firm unveiled positive top-line data with duvelisib for relapsed or refractory CLL/SLL.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription